Publicaciones en colaboración con investigadores/as de Charité (15)

2024

  1. Event-free survival by residual cancer burden with pembrolizumab in early-stage TNBC: exploratory analysis from KEYNOTE-522

    Annals of Oncology, Vol. 35, Núm. 5, pp. 429-436

  2. IMpassion132 double-blind randomised phase III trial of chemotherapy with or without atezolizumab for early relapsing unresectable locally advanced or metastatic triple-negative breast cancer

    Annals of Oncology, Vol. 35, Núm. 7, pp. 630-642

2023

  1. A Phase I Study of the Pan-Notch Inhibitor CB-103 for Patients with Advanced Adenoid Cystic Carcinoma and Other Tumors

    Cancer Research Communications, Vol. 3, Núm. 9, pp. 1853-1861

  2. Prognostic and predictive impact of gene expression in node-positive early breast cancer patients receiving dose-dense versus standard-dose adjuvant chemotherapy

    Molecular Oncology, Vol. 17, Núm. 6, pp. 1060-1075

  3. Real-world outcomes of single-stage spinal cord stimulation in chronic pain patients: A multicentre, European case series

    Interventional Pain Medicine, Vol. 2, Núm. 3

2022

  1. Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer

    New England Journal of Medicine, Vol. 386, Núm. 6, pp. 556-567

  2. Gene signatures in patients with early breast cancer and relapse despite pathologic complete response

    npj Breast Cancer, Vol. 8, Núm. 1

  3. Multiple Bayesian network meta-analyses to establish therapeutic algorithms for metastatic triple negative breast cancer

    Cancer Treatment Reviews, Vol. 111

2021

  1. A novel circulating microRNA for the detection of acute myocarditis

    New England Journal of Medicine, Vol. 384, Núm. 21, pp. 2014-2027

  2. Anthracyclines strike back: Rediscovering non‐pegylated liposomal doxorubicin in current therapeutic scenarios of breast cancer

    Cancers, Vol. 13, Núm. 17

  3. Real-world outcomes using a spinal cord stimulation device capable of combination therapy for chronic pain: A european, multicenter experience

    Journal of Clinical Medicine, Vol. 10, Núm. 18

  4. The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group

    npj Breast Cancer, Vol. 7, Núm. 1

2020

  1. Efficacy and Safety of Trastuzumab Emtansine plus Capecitabine vs Trastuzumab Emtansine Alone in Patients with Previously Treated ERBB2 (HER2)-Positive Metastatic Breast Cancer: A Phase 1 and Randomized Phase 2 Trial

    JAMA Oncology, Vol. 6, Núm. 8, pp. 1203-1209

2017

  1. Tumor-infiltrating lymphocytes in Breast Cancer and implications for clinical practice

    Biochimica et Biophysica Acta - Reviews on Cancer, Vol. 1868, Núm. 2, pp. 527-537

2012

  1. Molecular subclasses of breast cancer: How do we define them? The IMPAKT 2012 working group statement

    Annals of Oncology, Vol. 23, Núm. 12, pp. 2997-3006